Androgen independent progression in prostate cancer: Risk factors

By Auzanneau C.   Irani J.   Dahmani L.   Ouaki F.   Pires C.   Dore B.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 26-26

Elsevier

Access to resources Recommend Favorite

Chemotherapy for the Treatment of Hormone-Refractory Prostate Cancer

By Petrylak D.P.  

European Urology Supplements, Vol. 1, Iss. 2, 2002-05 ,pp. : 15-23

Elsevier

Access to resources Recommend Favorite

Serum prostate-specific antigen and the biologic progression of prostate cancer

By Kabalin J.N.   McNeal J.E.   Johnstone I.M.   Stamey T.A.  

Urology, Vol. 46, Iss. 1, 1995-07 ,pp. : 65-70

Elsevier

Access to resources Recommend Favorite

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

By Benaim E.A.   Pace C.M.   Lam P.M.   Roehrborn C.G.  

Urology, Vol. 59, Iss. 1, 2002-01 ,pp. : 73-78

Elsevier

Access to resources Recommend Favorite

Genetic pathways and new progression markers for prostate cancer defined by microsatellite allelotyping

By Knobloch Rolf   Konrad Lutz   Barth Peter   Brandt Heidrun   Wille Sebastian   Heidenreich Axel   Moll Roland   Hofmann Rainer  

Der Urologe A, Vol. 43, Iss. 3, 2004-09 ,pp. : 149-152

Springer Publishing Company

Access to resources Recommend Favorite